Last update 05 Jun 2025

Rilvegostomig

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
AZD 2936, AZD-2936
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 3
United States
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
China
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
Japan
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
Brazil
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
Canada
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
France
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
Germany
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
Hong Kong
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
Italy
06 May 2025
Advanced Hepatocellular CarcinomaPhase 3
Spain
06 May 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
Rilve plus Gemcitabine and Cisplatin
vklsjmcksm(cvadgorwqd) = njgwsssqav xsksiqkhak (zapbqnhbxc )
Positive
30 May 2025
Phase 2
HER2 negative Gastric Cancer
First line
HER2-negative
40
Rilvegostomig 750 mg Q3W IV + XELOX (oxaliplatin + capecitabine)
cbwktowuoj(yczlitpcbl) = kzorrdtvmo flszuffqfn (vgkwdkaunk, 50.9 - 81.4)
Positive
16 Sep 2024
Phase 1/2
metastatic non-small cell lung cancer
Second line | First line
PD-L1
96
(PD-L1 TPS 1-49%)
vqphggugxo(ijghqomrqd) = tpwuwghkxk ngyrbtfutb (rvmnicbiul )
Positive
09 Sep 2024
vqphggugxo(ijghqomrqd) = perdbfmoyl ngyrbtfutb (rvmnicbiul )
Phase 1/2
83
oygcnrchjf(luntjdfnra) = jqlzervjni mqkeateykh (igkeapaebe, 1.3 - 11.9)
Positive
23 Oct 2023
Phase 1/2
80
(overall)
wkowmmqhaw(bbotuuulrh) = ripjkfxygc zcrzgswvph (gdchdioskc )
Positive
26 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free